Supramolecular complex sacubitril/valsartan - the first representative of a new class of drugs for the treatment of chronic heart failure
The average prevalence of сhronic heart failure in the adult population, according to the statistics of different countries, ranges from 1.5 % to 5.5 % and therefore the study of this problem and of finding new approaches to the treatment of сhronic heart failure is also still relevant at present....
Saved in:
| Main Authors: | T. V. Ashcheulova, K. M. Kompaniiets, N. M. Herasimchuk |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Zaporizhzhia State Medical and Pharmaceutical University
2019-12-01
|
| Series: | Patologìâ |
| Subjects: | |
| Online Access: | http://pat.zsmu.edu.ua/article/view/188964/189447 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Baseline left ventricular ejection fraction predicts the magnitude of improvement in patients taking sacubitril/valsartan
by: José-Manuel Rubio-Campal, et al.
Published: (2025-06-01) -
Potential of valsartan+sacubitril therapy in hypertensive heart disease
by: A. G. Ovchinnikov, et al.
Published: (2021-08-01) -
Pathogenetic justification of sacubitril / valsartan use in respiratory-cardial comorbidity
by: T. V. Ashcheulova, et al.
Published: (2023-01-01) -
EFFECTS OF SACUBITRIL/VALSARTAN ON THE ARTERIAL STIFFNESS AND LEFT VENTRICULAR-ARTERIAL COUPLING IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION
by: Zh. D. Kobalava, et al.
Published: (2018-05-01) -
In‐Hospital or Out‐of‐Hospital Initiation of Sacubitril/Valsartan Versus Valsartan in Patients With Mildly Reduced or Preserved Ejection Fraction After A Worsening Heart Failure Event: The PARAGLIDE‐HF Trial
by: Nina Nouhravesh, et al.
Published: (2025-03-01)